pirozadil has been researched along with Apolipoprotein B-100, Familial Defective in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cuchi Alfaro, C; Cuchi Alfaro, MT; Cuchi de la Cuesta, C | 1 |
| Ishikawa, Y; Saito, Y; Shinomiya, M; Shirai, K; Yoshida, S | 1 |
2 other study(ies) available for pirozadil and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
[Clinical evaluation of pirozadil, administered continuously over four and a half years, in patients with hyperlipoproteinemia type IIa].
Topics: Aged; Anticholesteremic Agents; Cholesterol; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyridines | 1989 |
Effect of pirozadil on lipids, lipoproteins and apolipoproteins in Japanese with type IIa hyperlipoproteinemia.
Topics: Apolipoproteins; Body Weight; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Japan; Lipids; Lipoproteins; Male; Middle Aged; Pyridines | 1987 |